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A B S T R A C T
Enzyme replacement therapy (ERT) has been shown to stabilize certain aspects of Fabry disease (FD). However,
in some patients on ERT, high antibody titres have been documented, with limited clinical improvement in
systemic manifestations and often with significant adverse drug reactions. We present two related adolescent
males with a 4.5 kb GLA deletion, not amenable to chaperone therapy, leading to profound reduction in α-
galactosidase A (α-gal A) enzyme activity. Over a 3-year period of ERT, increasing IgG antibody titres against α-
gal A were noted. After starting ERT serial urine globotriaosylceramide (Gb3) measurements showed an upward
trend from 333 to 2260 μg/mmol creatinine for patient 1 and 1165 to 2260 μg/mmol creatinine for patient 2.
Markedly increased levels of urine and plasma globotriaosylsphingosine (Lyso-Gb3) analogues were also found.
The patients experienced recurrent infusion-associated reactions necessitating premedication and prolonged
infusion times. Over the 3-year period of ERT, the patients experienced continued malaise, gastrointestinal
symptoms and neuropathic pain. In addition, they had increasing anxiety related to their disease and apparent
lack of response to ERT which led to a decision to ultimately stop ERT. No other approved treatment options are
currently available for these patients. It is possible that the rapid development of the high antidrug neutralizing
antibody (ADA) titres is related to the large GLA deletion leading to virtually absent enzyme activity. It remains
unclear if their symptomatology during the period of receiving ERT is related to lack of its efficacy, the rising
ADA titres, or both. These two patients highlight the need for further research into the management of antidrug
antibodies and additional therapeutic approaches for FD.
Synopsis: The development of very high antidrug antibody titres in response to ERT in two related adolescent
males with FD highlight the need for other therapeutic options for patients in whom ERT or other currently
approved therapies does not meet their treatment needs.
1. Introduction
Fabry disease (FD) (OMIM #301500) is an X-linked multisystem
lysosomal storage disorder (LSD) caused by a deficiency of α-galacto-
sidase A enzyme (α-gal A, EC 3.2.1.22) also known as (ceramide tri-
hexosidase). Several treatment modalities are currently approved in-
cluding enzyme replacement therapy (ERT) in the forms of agalsidase
alfa (0.2 mg/kg intravenous (IV) every 2 weeks, Replagal™, Shire/
Takeda Pharmaceutical, Lexington, MA, USA) and agalsidase-beta
(1.0 mg/kg IV every 2 weeks, Fabrazyme®, Sanofi Genzyme,
Cambridge, MA, USA) and chaperone therapy with migalastat (123 mg
capsule taken orally every other day, Galafold™, Amicus Therapeutics,
Cranbury, NJ, USA) [20]. ERT has been shown to stabilize disease
progression of the nephropathy and the cardiomyopathy and reduces
gastrointestinal symptoms such as diarrhea, nausea, cramping, vo-
miting and heartburn [16]. In Canada, ERT treatment indications are
based on the most recent guidelines published by the Canadian Fabry
Disease Initiative (CFDI) (now CFDI-National Registry [NR]) (Sirrs et al.
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2019, [36]) and these include significant renal disease, cardiac disease
and/or neurologic disease. Gastrointestinal symptoms (GI) can be an
indication to treat provided that symptoms are affecting quality of life
or growth and have been unresponsive to other treatments for six
months or greater. Neuropathic pain unresponsive to other measures as
the sole indication for ERT can be tried for a year recognizing that re-
sponse is minimal in many patients. ELISA assays have been used by
ERT manufacturers who have identified IgG antidrug antibodies in
many patients [7,33,39]. These antibodies are more frequent in males
than females and in more patients receiving agalsidase beta than
agalsidase alfa and associated with higher urine Gb3 and plasma Lyso-
Gb3 levels suggesting reduced action of α-gal A as reviewed by [14].
Neutralizing antidrug antibodies to ERT in Fabry disease were first
reported in 2004. The neutralization was identified in vitro with the
highest published antibody titre to agalsidase alfa or beta of 1/32768
[27]. The association of agal-A antidrug antibody (ADA) with wor-
sening clinical outcomes in FD has been reported by an increasing
number of authors as summarized recently [23]. In a few patients, ti-
tration studies have shown a total absence of plasma α-gal A activity
during agalsidase infusion suggesting that complete inactivation of the
infused enzyme can occur in the presence of neutralizing antibody [26].
However, there have been limited publications on the clinical mani-
festations and therapeutic challenges of FD patients with high ADA ti-
tres and severe infusion-associated reactions (IARs). Here we report
treatment challenges caused by the heightened immune response in two
male adolescents who received ERT for up to three years.
2. Case presentations
Two male first cousins described below are part of a large kindred
with FD. Upon confirming the FD diagnosis, both patients were enrolled
in the CFDI study and the recommended schedule of baseline clinical
assessments as per the CFDI protocol was followed [35]. The patients
were both approved for ERT on the basis of neuropathic pain and
gastrointestinal manifestations, unresponsive to standard medical
management. They were subsequently randomized through the CFDI
protocol to receive agalsidase beta. Of note these are the first males in
this kindred to receive ERT. Their affected maternal uncle, now in his
40's, has classical disease with angiokeratomas, cornea verticillata,
renal failure and cardiomyopathy but has declined any approved or
experimental therapies. The mothers of these 2 cousins are confirmed
manifesting carriers.
Patient 1 was diagnosed at 10 years of age. The diagnosis of FD had
just been established in his maternal uncle. Patient 1 had long-standing
intractable abdominal pain with nausea, cramping, diarrhea, con-
stipation, and acroparesthesiae in his hands and feet dating back to
early childhood. There was no symptomatic improvement with
6 months of treatment with ibuprofen, acetaminophen, and gabapentin.
Intravenous ERT with agalsidase beta at recommended doses was in-
itiated. While receiving ERT he required premedication with acet-
aminophen and antihistamines, as well as prolongation of infusion
times to minimize IARs including fever and chills.
Patient 2 was diagnosed at 9 years of age after the diagnosis of FD
was established in his maternal uncle. He had long-standing intractable
abdominal pain and acroparesthesiae, as well as heat intolerance,
headaches, and tinnitus. Symptoms were unchanged after 6 months of
treatment with omeprazole, loperamide, acetaminophen, and ibu-
profen. He thus was started on ERT with agalsidase beta at standard
dose. He also required premedication with acetaminophen and anti-
histamines, as well as prolongation of infusion times to minimize IARs
with fever, chills and abdominal pain.
After 3 years of ERT, with no improvement in symptoms of severe
abdominal pain and acroparesthesiae, ERT was discontinued in both
patients. They continue to experience neuropathic pain and GI symp-
toms. Cardiac and renal function remained normal during the 3 years of
ERT and the subsequent 3 years as expected given their young age.
Echocardiograms and cardiac magnetic resonance images have re-
mained normal and there has been no evidence of proteinuria with
normal eGFR.
3. Methods
Sanger sequencing of the GLA gene and α-gal A enzyme activity
measured by standard fluorometric enzyme assay were performed by
Mount Sinai Genetics Testing Laboratory (Dept. of Genetics and
Genomic Sciences, Mount Sinai School of Medicine, New York, NY,
USA).
IgG antidrug antibodies (ADA) against agalsidase beta were mea-
sured in serum samples by the enzyme linked immunosorbent assay
(ELISA) (Genzyme Clinical Specialty Lab, Framingham, MA, USA), and
IgE antibodies were measured by fluoroenzyme immunoassay
(Genzyme Clinical Specialty Lab, Framingham, MA, USA) as previously
described [7,39].
Serum samples were evaluated for the presence of anti-(α-Gal A)
antibodies as previously described [38]. To assess neutralizing activity
in vitro, serum (10 μL) was incubated with a standard amount of re-
combinant α-galactosidase A (agalsidase beta, 2.1 ng). Enzyme activity
was determined after 10 min of incubation at room temperature. The
serum dilution that resulted in 50% reduction of the enzyme activity
was recorded (IC50). Titre is expressed as 1/x in which x is the dilution
factor of serum. Appropriate controls were included and assays were
done in triplicate.
Urinary Gb3 normalized to creatinine was analyzed according to the
mass spectrophotometric method developed by Auray-Blais et al. [5].
Briefly, a homogenized urine specimen was deposited on a 10 × 10 cm
filter paper (Whatman-GE 903) and dried at ambient air. The specimen
was stored in a hermetic plastic bag at room temperature. For the
analysis, a 5-cm filter paper disk was punched out and spiked with
internal standards (100 μL of Gb3(C17:0) (1 μg/100 μL) and 100 μL of
creatinine-D3 (40 μg/100 μL)). Thereafter, the paper disk was eluted
with 4 mL of MeOH. The sample was separated by liquid chromato-
graphy using a Zorbax Bonus-RP Guard column (4.6 × 12.5 mm;
Agilent Technologies, Santa Clara, CA, USA) and an Alliance 2795
HPLC system (Waters Corp., Milford, USA). The total of 8 Gb3 isoforms
(C16:0, C18:0, C20:0, C22:1, C22:0, C24:1, C24:0, C24:OH), the
Gb3(C17:0) internal standard, the creatinine and the creatinine-D3 in-
ternal standard were analyzed using the multiple reaction monitoring
mode (MRM) with a Quattro Micro triple quadrupole mass spectro-
meter (Waters Corp.). Seven-point calibration curves were used for the
quantitation of Gb3 (0–20 μg/mL) and creatinine (0–10 μmol/mL).
Urine sample aliquots from an untreated Fabry male and an untreated
Fabry female were used for the quality controls and analyzed with a
tolerance of± 25%.
Analysis of plasma Lyso-Gb3 and analogues was conducted on
plasma specimens collected in EDTA tubes and stored at -20 °C. The
method developed by Boutin et al. [8,9], was used for the analysis of
Lyso-Gb3 and analogues in plasma. A plasma volume of 100 μL was
spiked with 500 μL of the glycinated Lyso-Gb3 standard (Lyso-Gb3-Gly,
10 nM in methanol). The samples were purified by solid phase ex-
traction using a mixed-mode strong cation exchange (MCX) cartridge
and separated by ultra-performance liquid chromatography (UPLC)
using a BEH C18 column (1.7-μm, 2.1 × 50 mm, Waters Corp.) and an
Acquity I-Class system (Waters Corp). Lyso-Gb3 and its 6 analogues
(-C2H4, -H2, +O, +H2O, +H2O2, +H2O3), and the Lyso-Gb3-Gly in-
ternal standard were analyzed using the MRM mode with a Xevo TQ-S
mass spectrometer (Waters Corp.). A seven-point calibration curve
(0–400 nM) was used for the quantitation of Lyso-Gb3 and its analogues
in plasma. Plasma sample aliquots from an untreated Fabry male and an
untreated Fabry female were used for the quality controls and analyzed
with a tolerance of± 20%.
The method developed by Lavoie et al. [21,22] was used for the
analysis of Lyso-Gb3 and analogues in urine. Urine specimens were
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stored at -20 °C before analysis. A urine volume of 500 μL was spiked
with 500 μL of the glycinated Lyso-Gb3 standard (Lyso-Gb3-Gly, 10 nM
in methanol). The samples were purified by solid phase extraction using
a MCX cartridge, and separated by ultra-performance liquid chroma-
tography (UPLC) using an Atlantis HILIC Silica column (3 μm,
2.1 × 50 mm, Waters Corp.) and an Acquity I-Class system (Waters
Corp). Lyso-Gb3 and its 7 analogues (-C2H4, -C2H4 + O, -H2, -H2 + O,
+O, +H2O2, +H2O3), and the Lyso-Gb3-Gly internal standard were
analyzed using the MRM mode with a Xevo TQ-S mass spectrometer
(Waters Corp.). An eleven-point calibration curve (0–700 nM) was used
for the quantitation of Lyso-Gb3 and its analogues in urine. The crea-
tinine concentration was used to normalize the Lyso-Gb3 results [1].
Urine sample aliquots from an untreated Fabry male and an untreated
Fabry female were used for the quality controls and analyzed with a
tolerance of± 20%.
4. Results
The GLA gene consists of 7 exons and covers 12 kilobases (kb) of
genomic DNA. Results of molecular testing in this family showed a
4.5 kb genomic GLA deletion, encompassing ~37% of the gene, in all
affected family members tested. At the cDNA level, the deletion begins
at 533 bases upstream from the first codon of GLA and extends to nu-
cleotide 1277 (GLAc.370-533_c.1277del4.5).
Biochemical α-gal A enzyme activity testing in patient 1 revealed
very low enzyme activity in leukocytes of 0.19 nmol/h/mg protein
(normal range 12.8–74.1 nmol/h/mg protein) and plasma 0.30 nmol/
h/mL (normal range 6.20–18.6 nmol/h/mL). In patient 2, results
showed similarly very low α-galA enzyme activity in leukocytes
1.21 nmol/h/mg protein and in plasma 0.30 nmol/h/mL.
Results of serum IgG antibody titres for patients 1 and 2 in relation
to ERT time course are plotted in Fig. 1A. For patient 1, no baseline
antibody measurement was recorded prior to the start of ERT. IgG an-
tibody titre was 1:25,600 (2 months after starting ERT) and rose to as
high as 1:102,400. The results for IgE antibodies were consistently
negative, meaning there was less than 0.35 k-units of IgE antibodies per
litre of serum. There was one neutralizing antibody measurement per-
formed after approximately 2.5 years of ERT. This showed that 1 mL of
serum significantly inhibited 241 μg of enzyme in vitro. For patient 2,
IgG antibodies were measured and not present at baseline prior to the
start of ERT. At the highest, IgG antibody titre measured 1:25,600. IgE
antibodies were consistently negative. Neutralizing antibody tests were
performed on 2 occasions approximately 6 months apart. Successive
results showed that 1 mL of serum inhibited 17 and 42 μg of enzyme
activity in vitro.
Results of urinary Gb3 for patients 1 and 2 in relation to ERT time
course are plotted in Fig. 1B. For patient 1, urinary Gb3 showed an
upward trend despite ERT from 333 to a peak of 2260 μg/mmol crea-
tinine. Similarly, in patient 2, urinary Gb3 showed an upward trend
from 503 to a peak of 1250 μg/mmol creatinine. In patient 1, plasma
and urinary Lyso-Gb3 measured 77.3 nmol/L (normal value is
2.4 nmol/L) and 50 pmol/mmol creatinine respectively (normal value
is “not detected”) (Fig. 2 A and B). In patient 2, plasma and urinary
Lyso-Gb3 were measured as high as 79.5 nmol/L and 56 pmol/mmol
creatinine, respectively (Fig. 2 C and D) (See Supplemental Table 1 for
detailed Lyso-Gb3 values).
5. Discussion
This report documents the persisting very high ADA response to ERT
in two male adolescent FD patients receiving ERT with standard dose
agalsidase beta.
A key concern in the first FD ERT trials was immediate IARs. IARs
were originally felt to be IgE mediated but are now known to be
“anaphylactoid” (compound mediated) and IgG mediated consistent
with the fact that both our patients had persisting severe IARs but
remained IgE negative. Premedication protocols, usually a combination
of single dose acetaminophen or a non-steroidal anti-inflammatory
drug, antihistamine and corticosteroid, along with increasing infusion
time, to prevent such reactions have been established successfully and
are used as required [13]. While receiving ERT at recommended doses,
both patients required premedication which attenuated, but did not
prevent, IARs.
To date, there remains no common ADA assay used in the care of FD
patients. Assays are done via various techniques (ELISA, in vitro in-
hibition) and differ in their sensitivities and specificities which make
comparisons difficult. An attempt to develop a common assay has failed
(Schellenkens et al. 2008). Seroconversion with ADA is reported in 73%
males as opposed to 12% females treated with agalsidase beta. This is
likely due to complete absence of native enzyme in males with classical
FD while males with missense mutations, who express residual α-Gal A
enzyme activity, are far less likely to develop antibodies [39]. Neu-
tralizing antibodies detected in vitro may not correlate with in vivo
action. However, as identified by the method of Aerts, these antibodies
cross react with both agalsidase products, tend to be persistent and have
only been reported in males with FD [30]. Long-term effect of neu-
tralizing antibodies has been studied in detail, in particular, their im-
pact on clinical outcomes. Bénichou et al. [7] observed significantly
impaired Gb3 clearance in skin biopsies of patients treated with ERT
and high antibody titres. A correlation between ADA levels and plasma
Lyso-Gb3 has been confirmed [31]. The same has been reported for ADA
levels and urine Gb3 [30]. Similarly, when analyzing in vitro enzyme
inhibition in relation to plasma Lyso-Gb3 levels, disease severity scores
and subjective symptoms in a group of 168 patients, Lenders et al. [24]
confirmed higher Lyso-Gb3 levels, as well as worsening disease severity
scores in patients with serum-mediated enzyme inhibition. As well,
results reported by Auray-Blais et al. [3,4] from a large cohort of FD
patients in Taipei revealed that plasma and urine Lyso-Gb3 analogues
(+16), (+34), and (+50) were positively associated with the severity
of disease for the left ventricular mass index and also the Mainz Severity
Score Index when adjusted for age and gender. High levels of these
glycosphingolipids were also identified in children. Moreover, and si-
milar to the results obtained for patients 1 and 2 where the analogues of
Lyso-Gb3 in urine are markedly increased, a study in FD children
showed that the urine Lyso-Gb3 analogues are sometimes increased
greater than Lyso-Gb3 itself [2]. Sakuraba et al. [31] showed that there
was no difference noted in ADA with respect to type of ERT adminis-
tered (agalsidase alfa or beta) and did not recommend a therapy switch
in their antibody-positive patients.
The aim of ERT is to minimize FD symptoms, prevent disease pro-
gression and Gb3 and Lyso-Gb3 build up. We had previously measured
the levels of urine Gb3 in “liquid” urine specimens from 33 male FD
patients receiving ERT and the results ranged from 0.45 μg/mmol
creatinine to 129 μg/mmol creatinine [10]. These values were obtained
after conversion of the units from nM/mM creatinine to μg/mmol
creatinine. Only the 8 Gb3 isoforms analyzed on filter paper (C16:0,
C18:0, C20:0, C22:1, C22:0, C24:1. C24:0, C24:OH) were taken in ac-
count for the unit conversion, and the outlier values (over 1.5 times the
interquartile range) were excluded.
In both of our patients reported herein, urine Gb3 levels greatly
exceeded this range while receiving ERT suggesting a blunting or lack
of effectiveness of ERT in these 2 patients (Fig. 1B). Levels of Lyso-Gb3
and analogues in urine and plasma were also massively and persistently
elevated consistent with the suggested loss of ERT action. Lyso-Gb3
levels increased up to 46 and 40 times the normal values in urine, and
up to 70 and 43 times the normal values in plasma for patients 1 and 2,
respectively (Fig. 2).
The mechanisms by which neutralizing ADA can interfere with ERT
in FD have not been well studied. Lenders et al. [26] showed a reduc-
tion in plasma agalsidase activity during ERT infusion in Fabry patients
with neutralizing ADA consistent with direct antibody binding of the
enzyme. Three patients treated with Pegunigalsidase developed
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neutralizing ADA with transient altered drug pharmacokinetics with
lower area under the concentration curve, lower maximum observed
concentration and longer terminal half-life [34] also consistent with
direct ADA binding and inactivation of the infused enzyme. Other
mechanisms such as ADA interference with enzyme uptake into cells
and increased enzyme clearance are possible but have not been studied
in ADA in Fabry disease.
To overcome the ADA effect, immunomodulation therapy in re-
sponse to antibody formation has been initiated in other LSDs treated
with ERT [11]. Immunomodulation therapy has had documented suc-
cess in both Gaucher disease [12] and Pompe disease [29] and this has
enabled patients to continue ERT. Successful immunomodulation has
also been demonstrated in FD mouse models [15]. A study investigating
the effect of immunosuppression in renal transplant patients with FD on
antibody formation has provided valuable insights [25]. Im-
munosuppression was shown to decrease ADAs significantly in ERT
naive as well as treated patients. However, further studies are needed to
evaluate the clinical impact of lowering ADAs and its correlation with
biomarkers and clinical response. Patients with persistent very high
antibody titres may not respond to immunomodulation therapy [6].
Due to the demanding nature of an immunomodulation regime, its
potential side effects, and uncertain outcomes, the patients and their
families declined this approach. Immune tolerance induction through
dose escalation was considered as another alternative. However, this
option was also declined as impractical to due high cost. Rombach et al.
[30] reported that increased ERT dose by switching from agalsidase alfa
0.2 mg/kg to agalsidase beta 1.0 mg/kg in Fabry patients with ADA
resulted in lower plasma levels of both Lyso-Gb3 and Gb3. However,
Lenders et al. [26] described a small number of patients with
neutralizing antibody in whom the response to ERT dose increase was
quite variable; some patients had no response or only a transient re-
sponse in the short term as determined by the calculated plasma agal-
sidase activity by titration during ERT infusion. Further study is needed
to define the response to increased enzyme dosing in the presence of
neutralizing ADA. An alternate ERT formulation was considered,
however agalsidase alfa is structurally similar to agalsidase beta so si-
milar effects would very likely be elicited due to the patients' pre-
existing immune response. Several studies have found that all anti-
bodies showed complete cross-reactivity such that patients who
developed antibodies after treatment with agalsidase alfa or beta had
the same antibody titre toward the other [27,31]. Chaperone therapy
and substrate reduction therapy (SRT) are newer therapeutic options
that were also considered. However, the patients' mutations are not
amenable to the oral chaperone therapy option migalastat [17] leaving
only SRT as an option. The SRT lucerastat (Idorsia Pharmaceuticals
Ltd., Allschwil, Switzerland) is currently in a clinical trial phase but
only adults who meet entry criteria are presently eligible [18]. This
made both patients who are minors still ineligible for this SRT trial.
Gene therapy is another option that could be considered in the future
when the patients reach adulthood [19]. Such gene therapy trials are
currently underway in Canada [28]. However, pre-existing ADA could
in theory also interfere with agalsidase production by transfected cells
and little is known currently about ADA in gene therapy in lysosomal
diseases.
In conclusion, high ADA titres can pose a significant treatment
barrier for FD. We suggest that the recognition that a male FD patient is
not responding well to ERT is reason to look for the presence of high





















Collection date   Patient 1 Collection date   Patient 2
Aug-12 25600 Feb-13 0
Nov-12 51200 Jun-13 25600
Feb-14 51200 Nov-13 25600
Aug-14 102400 Jul-14 25600
Dec-14 102400 Dec-14 12800
Jan-15 51200 May-15 25600
Apr-15 102400 Jun-15 25600



























Fig. 1. A. IgG antibody titres by ELISA assay for patients 1 and 2 in relation to ERT time course. B. Urine Gb3 levels for patients 1 and 2 in relation to ERT time course.
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enzyme.
Routine periodic antibody screening in patients treated with ERT, as
well as markedly increased biomarker levels in biological fluids, will
allow early detection of neutralizing ADA and could permit early ERT
dose increase, immunomodulation treatment or a switch to a different
therapy option when it is possible. To date, there is no suitable treat-
ment available for our young patients. The patients presented here il-
lustrate the need for more research into other therapeutic options, such
as SRT, new chaperone therapies for mutations that are not amenable to
migalastat, or other novel treatment approaches for ADA reduction and
prevention to improve the efficacy of ERT (Stappers et al. 2020) [37], as
well as gene therapy.
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